Jpmorgan Chase & Co - Dec 31, 2024 SCHEDULE 13G Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)

Filing Manager: JPMORGAN CHASE & CO
Reporting Manager: JPMORGAN CHASE & CO.
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Shares outstanding: 105M shares
Disclosed Ownership: 5.69M shares
Ownership: 5.4%
Form type: SCHEDULE 13G
Date filed: 2/11/2025, 12:16 PM
Date of event: Dec 31, 2024
Next filing: Mar 6, 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
JPMORGAN CHASE & CO.	5.4%	5.69M	5.69M	0	Rachel Tsvaygoft	Vice President

Showing 1 to 1 of 1 entries